Meredith Regan, ScD
Assistant Professor of Medicine
Office phone: 617-632-2471
Preferred contact method: email
Area of ResearchStatistical Methods in Cancer Research.
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Regan received her ScD in Biostatistics from Harvard School of Public Health in 1998. After completing a fellowship at the Biometrics Center at Beth Israel Deaconess Medical Center, she joined the faculty as a biostatistician and Instructor of Medicine, Harvard Medical School. In 2003 she joined the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology where she is Senior Research Scientist and Assistant Professor of Medicine, Harvard Medical School. Dr. Regan was appointed Group Statistician for the International Breast Cancer Study Group (IBCSG) in 2009.
ResearchStatistical Methods in Cancer Research.
Dr. Regan has collaborated with DF/HCC genitourinary cancers researchers since 2000. She is Director of the Biostatistics Cores of the DF/HCC Prostate Cancer SPORE and DF/HCC Kidney Cancer SPORE grants and consulting biostatistician for the Harvard/Michigan Prostate Cancer Biomarker Clinical Center EDRN grant.
Dr. Regan is Group Statistician for the International Breast Cancer Study Group (IBCSG). She is the lead statistician for a suite of three international randomized clinical trials (the "STP trials") evaluating the role of ovarian function suppression and adjuvant endocrine therapy in premenopausal women with early-stage breast cancer. With Prof. Giuseppe Viale and Dr. Olivia Pagani, Dr. Regan is co-PI of the IBCSG's Susan G. Komen Promise Grant which established an international collaboration of researchers to determine, among premenopausal (TEXT trial) and postmenopausal women (trial BIG 1-98), features of the disease or patient that inform selection of endocrine therapy for individual patients.
- Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
- Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7099-105. Epub 2009 Nov 3.
- Regan MM, ODonnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials. Ann Oncol 2009 Jul 24 [Epub ahead of print].
- Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009;69:5568-74.
- Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thrlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: Who receives chemotherapy? Ann Oncol 2008;19:1231-41.
- Rasmussen BB, Regan MM, Lykkesfeldt AE, DellOrto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Mry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thrlimann B, Coates AS, Viale G, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-28.
- Viale G, Regan MM, Maiorano E, Mastropasqua MG, DellOrto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, hlschlegel C, Thrlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-52.
- Taplin M-E, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Docetaxel, estramustine and 15 month androgen deprivation for men with prostate specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24:5408-13
- Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayshi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the effectiveness of androgen deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7.
- Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009;15:4706-4711.
- Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN. Does arterial spin labeling MRI measured tumor perfusion correlate with response of renal cell cancer to antiangiogenic therapy in a mouse model? Radiology 2009;251:731-42.